424B5 1 ny20082832x1_424b5.htm 424B5

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-295960

PROSPECTUS SUPPLEMENT

(To Prospectus dated June 2, 2026)

Up to $19,135,717

Common Stock

We have entered into a sales agreement, dated as of October 1, 2026 (the “Sales Agreement”) with Titan Partners Securities LLC (the “Agent”) relating to shares of our common stock, par value $0.0001 per share (“common stock”), offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $19,135,717 from time to time through the Agent, acting as our sales agent.

The aggregate market value of our outstanding shares of common stock held by non-affiliates was $57,407,153 based on 4,196,009 shares of common stock outstanding as of September 29, of which 3,585,706 shares are held by non-affiliates, and a per share price of $16.01 based on the closing sale price of our common stock on August 6, 2026. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in a public primary offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. During the 12-month period prior to and including the date of this prospectus supplement, we did not offer any securities pursuant to General Instruction I.B.6 of Form S-3.

Our common stock is listed on the Nasdaq Capital Market (Nasdaq) under the symbol “VHC.” On September 29, 2026, the last reported sale price of our common stock on Nasdaq was $10.32 per share.

Sales of shares of our common stock under this prospectus supplement and the accompanying prospectus, if any, may be made by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the Nasdaq Capital Market, on any other existing trading market for the common stock or to or through a market other than on an exchange. In addition, with our prior written approval, the Agent may also sell the common stock by any other method permitted by law, including in privately negotiated transactions or block transactions.

The Agent is not required to sell any specific number or dollar amount of shares of our common stock. The Agent has agreed to use its commercially reasonable efforts consistent with its normal trading and sales practices, on mutually agreed terms between the Agent and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. The Agent will be entitled to compensation under the terms of the Sales Agreement at a commission rate equal to 3% of the gross sales price of common stock that it sells pursuant to the Sales Agreement. The net proceeds from any sales under this prospectus supplement and the accompanying prospectus will be used as described under “Use of Proceeds.” The proceeds we receive from sales of our common stock, if any, will depend on the number of shares actually sold and the offering price of such shares. See “Plan of Distribution” beginning on page S-15 of this prospectus supplement for additional information regarding compensation to be paid to the Agent and estimated offering expenses.

In connection with the sale of common stock on our behalf, the Agent may be deemed to be an “underwriter” within the meaning of the Securities Act, and its compensation as Agent may be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the Agent with respect to certain liabilities, including liabilities under the Securities Act.

Investing in our securities involves significant risks. Please read the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-5 of this prospectus supplement, and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus supplement and the accompanying prospectus.

Neither the Securities and Exchange Commission (the SEC) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

Titan Partners

The date of this prospectus supplement is October 1, 2026


			Page
About this Prospectus Supplement			S-ii
Prospectus Supplement Summary			S-1
The Offering			S-4
Risk Factors			S-5
Forward-Looking Statements			S-7
Use of Proceeds			S-8
Dividend Policy			S-9
Dilution			S-10
Material U.S. Federal Income Tax Considerations For Non-U.S. Holders			S-11
Plan of Distribution			S-15
Legal Matters			S-17
Experts			S-17
Where You Can Find More Information			S-17
Incorporation by Reference			S-17


			Page
About this Prospectus			ii
Prospectus Summary			1
Risk Factors			5
Forward-Looking Statements			6
Use of Proceeds			7
Description of Capital Stock			8
Description of Debt Securities			8
Description of Depositary Shares			15
Description of Warrants			17
Description of Subscription Rights			18
Description of Purchase Contracts			18
Description of Units			19
Plan of Distribution			21
Legal Matters			23
Experts			23
Where You Can Find More Information			23
Incorporation by Reference			24


Assumed offering price per share		$10.32
Net tangible book value per share as of June 30, 2026	$3.57
Increase per share attributable to new investors	$1.91
Net tangible book value per share after giving effect to this offering	$5.48
Dilution per share to new investors		$4.84